Loading TFX detail
Loading ticker data...
Loading TFX detail
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets.
The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Chart data unavailable
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company's previously announced program ahead of schedule. The announcements reflect the Board's continued focus on strong governanc.
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today issued the following statement regarding the Company's recent announcement: “We welcome Teleflex's newfound openness to consider all strategic alternatives. As a next step, we believe the Board of Directors should form a Strategic Review sub-committee with new independent directors, including a shareholder represent.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. (“Irenic”). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views a.
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil on any given day. Those two items have dictated the direction of stocks, bonds, precious metals, and crypto since... Here Are Friday's Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More.
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, one of the largest shareholders of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX) with 2% ownership, today sent the below letter to the Company's Board of Directors (the “Board”) regarding its refusal to engage with potential acquirors, despite receiving interest from multiple credible parties. The letter also urges the Board to immediately take a more constructive and responsible approach to evaluating strategic alterna.
Shares of Teleflex Incorporated (NYSE: TFX - Get Free Report) have earned an average recommendation of "Hold" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company.
DALLAS--(BUSINESS WIRE)--o9, a leading enterprise AI software platform provider for transforming planning and decision-making, today announced that Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, is now live globally with Demand Planning and Supply Planning on the o9 platform. This deployment supports Teleflex's multi-year effort to enhance its end-to-end integrated business planning and supply chain management capabilities. With Demand Planning and Supply.
Citigroup Inc. reduced its position in shares of Teleflex Incorporated (NYSE: TFX) by 40.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,004 shares of the medical technology company's stock after selling 14,020 shares during the period. Citigroup
Focus Partners Advisor Solutions LLC acquired a new position in shares of Teleflex Incorporated (NYSE: TFX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,178 shares of the medical technology company's stock, valued at approximately $1,362,000. A number of
Teleflex faces a complex transition after divesting major business units at low multiples, creating uncertainty around future earnings power. Teleflex now trades at 17–18x forward earnings with a strong balance sheet and mid-single-digit organic growth, yet recent strategic actions have impaired conviction. 2026 guidance is clouded by stranded costs and transition agreements, but normalized earnings could reach $8–9 per share, offering potential upside above $150.
Teleflex Q4 earnings and revenues miss estimates as margins shrink, but shares rise 1.7% after hours amid 2026 growth guidance and portfolio reshuffle.
Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Teleflex (TFX) came out with quarterly earnings of $1.93 per share, missing the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.89 per share a year ago.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven b.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from con.
